OptimizeRx Reaffirms 2023 Guidance 
<p><a href='https://financialmodelingprep.com/financial-summary/OPRX'>OptimizeRx Corporation (NASDAQ:OPRX)</a> reaffirmed its 2023 over 10% revenue growth outlook, provided a positive update concerning the visibility it now has into achieving that target, and also introduced longer-term goals of reaching $100-120 million revenue and 20% EBITDA margin within the next 18-24 months. </p>
<p>Underpinning its confidence in the latter, management cites strong macro tailwinds, expanded offerings and strengthening commercial momentum. </p>
<p>Analysts at RBC Capital find all these encouraging but also noted growth thus far has been choppy, and absent M&A, achieving even the low end of the long-term revenue target would require a meaningful multi-year acceleration from 2022 and 2023 levels.</p>

NASDAQ:OPRX